Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.-MedSci.cn

Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.

Chowdhury, S; Mateo, J; Gross, M; Armstrong, AJ; Cruz-Correa, M; Piulats, JM; Blay, JY; Li, M; Rivas, D; Quintero, L; Castro, H; Nkobena, A; Raponi, M; Pelham, R; Landers, M; Montgomery, RB

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务